Clinical Trials Directory

Trials / Unknown

UnknownNCT01125865

Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture

Uncovered Self-expandable Metal Stent Versus DoubleLayer Plastic Stent for Malignant Hilar Stricture: a Prospective Randomized Multicenter Trial

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Soon Chun Hyang University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The overall median survival of nonresectable malignant hilar obstruction in most series has been less than 6 months. Most patients with malignant hilar obstruction present with advanced disease, making palliative endoscopic drainage the principal therapeutic option. However, the optimal endoscopic management strategy is contentious. Almost all of the published data comparing plastic and metallic stents relate to distal tumors (those of the pancreas, common bile duct and ampulla). Stent patency, complication rates, and cost-effectiveness have favored metallic stents when compared with plastic stents in patients with distal malignant obstruction expected to live at least 3 to 6 months. There are few comparative study as to whether self-expanding metallic or plastic stent, especially DLS (double layer plastic stent) are preferable in the technical success, stent patency, and cost-effectiveness for palliating malignant hilar obstruction. The study was designed to compare the the technical success, stent patency, and cost-effectiveness of self-expandable metal stent and DLS in patients with malignant hilar obstruction.

Conditions

Interventions

TypeNameDescription
DEVICESEMS insertionSelf-expandable metallic stent will be inserted for malignant hilar obstruction.
DEVICEDLS insertionDoubleLayer plastic stent will be inserted for malignant hilar obstruction.

Timeline

Start date
2010-05-01
Primary completion
2011-07-01
Completion
2011-12-01
First posted
2010-05-19
Last updated
2011-03-10

Locations

4 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01125865. Inclusion in this directory is not an endorsement.